Press "Enter" to skip to content

What Happens When You Inject Yourself With Reptile Venom Peptides Marketed As FDA-Approved Weight Loss Drugs

By

 

Dr. Bryan Ardis was at the forefront of pointing out the use of different venoms in not just what produced the CONvids, but also in a number of blood pressure medications, cosmetics and a variety of supplements approved by the unconstitutional Food and Drug Administration.  Not only did he reveal this, but at last year’s first annual Healing for the A.G.E.S. conference (Use promo code TIM and save), he and other doctors provided lots of natural remedies to these venoms.  Yet, what happens when you inject yourself with these reptile venom peptides that have been marketed as weight-loss drugs?

Lance D. Johnson has the effects of pumping this stuff into your body.

As weight loss drugs like Ozempic and Wegovy become popularized by pill-pushing allopathic doctors, new evidence suggests there are serious, life-altering risks with these new drugs. According to a new study, Ozempic an Wegovy users are at an elevated risk of developing a “potentially blinding eye condition.” This is what happens when you inject reptile venom peptides.

Venomous Ozempic and Wegovy increase risk of blindness

The study, published in JAMA Ophthalmology, has raised concerns about an association between semaglutide, a medication used to manage type 2 diabetes and obesity, and an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) This serious condition (NAION) can lead to sudden vision loss and is characterized by damage to the optic nerve.

The study, led by Jimena Tatiana Hathaway, MD, MPH and colleagues, investigates a link between semaglutide use and the incidence of NAION. The researchers conducted a retrospective matched cohort study using data from a centralized registry covering patients who were evaluated by neuro-ophthalmologists at an academic institution between December 2017 and November 2023.

The study included 16,827 patients who had no prior history of NAION. Among these, 710 patients had type 2 diabetes (T2D) and 979 were overweight or obese. Within these groups, patients were either prescribed semaglutide or non–glucagon-like peptide receptor agonist (GLP-1 RA) medications for managing their conditions…

READ FULL ARTICLE HERE… (thewashingtonstandard.com)

Live Stream + Chat (zutalk.com)

 


Home | Caravan to Midnight (zutalk.com)

We Need Your Help To Keep Caravan To Midnight Going,

Please Consider Donating To Help Keep Independent Media Independent

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Breaking News: